Cargando…

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

BACKGROUND: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that S...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsiang-Chun, Shiou, Yi-Lin, Jhuo, Shih-Jie, Chang, Chia-Yuan, Liu, Po-Len, Jhuang, Wun-Jyun, Dai, Zen-Kong, Chen, Wei-Yu, Chen, Yun-Fang, Lee, An-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638/
https://www.ncbi.nlm.nih.gov/pubmed/30935417
http://dx.doi.org/10.1186/s12933-019-0849-6
_version_ 1783408062158077952
author Lee, Hsiang-Chun
Shiou, Yi-Lin
Jhuo, Shih-Jie
Chang, Chia-Yuan
Liu, Po-Len
Jhuang, Wun-Jyun
Dai, Zen-Kong
Chen, Wei-Yu
Chen, Yun-Fang
Lee, An-Sheng
author_facet Lee, Hsiang-Chun
Shiou, Yi-Lin
Jhuo, Shih-Jie
Chang, Chia-Yuan
Liu, Po-Len
Jhuang, Wun-Jyun
Dai, Zen-Kong
Chen, Wei-Yu
Chen, Yun-Fang
Lee, An-Sheng
author_sort Lee, Hsiang-Chun
collection PubMed
description BACKGROUND: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that SGLT2i, empagliflozin can improve cardiac hemodynamics in non-diabetic hypertensive heart failure. METHODS AND RESULTS: The hypertensive heart failure model had been created by feeding spontaneous hypertensive rats (SHR) with high fat diet for 32 weeks (total n = 13). Half SHRs were randomized to be administered with SGLT2i, empagliflozin at 20 mg/kg/day for 12 weeks. After evaluation of electrocardiography and echocardiography, invasive hemodynamic study was performed and followed by blood sample collection and tissue analyses. Empagliflozin exhibited cardiac (improved atrial and ventricular remodeling) and renal protection, while plasma glucose level was not affected. Empagliflozin normalized both end-systolic and end-diastolic volume in SHR, in parallel with parameters in echocardiographic evaluation. Empagliflozin also normalized systolic dysfunction, in terms of the reduced maximal velocity of pressure incline and the slope of end-systolic pressure volume relationship in SHR. In histological analysis, empagliflozin significantly attenuated cardiac fibrosis in both atrial and ventricular tissues. The upregulation of atrial and ventricular expression of PPARα, ACADM, natriuretic peptides (NPPA and NPPB), and TNF-α in SHR, was all restored by treatment of empagliflozin. CONCLUSIONS: Empagliflozin improves hemodynamics in our hypertensive heart failure rat model, associated with renal protection, attenuated cardiac fibrosis, and normalization of HF genes. Our results contribute some understanding of the pleiotropic effects of empagliflozin on improving heart function.
format Online
Article
Text
id pubmed-6444638
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64446382019-04-11 The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats Lee, Hsiang-Chun Shiou, Yi-Lin Jhuo, Shih-Jie Chang, Chia-Yuan Liu, Po-Len Jhuang, Wun-Jyun Dai, Zen-Kong Chen, Wei-Yu Chen, Yun-Fang Lee, An-Sheng Cardiovasc Diabetol Original Investigation BACKGROUND: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that SGLT2i, empagliflozin can improve cardiac hemodynamics in non-diabetic hypertensive heart failure. METHODS AND RESULTS: The hypertensive heart failure model had been created by feeding spontaneous hypertensive rats (SHR) with high fat diet for 32 weeks (total n = 13). Half SHRs were randomized to be administered with SGLT2i, empagliflozin at 20 mg/kg/day for 12 weeks. After evaluation of electrocardiography and echocardiography, invasive hemodynamic study was performed and followed by blood sample collection and tissue analyses. Empagliflozin exhibited cardiac (improved atrial and ventricular remodeling) and renal protection, while plasma glucose level was not affected. Empagliflozin normalized both end-systolic and end-diastolic volume in SHR, in parallel with parameters in echocardiographic evaluation. Empagliflozin also normalized systolic dysfunction, in terms of the reduced maximal velocity of pressure incline and the slope of end-systolic pressure volume relationship in SHR. In histological analysis, empagliflozin significantly attenuated cardiac fibrosis in both atrial and ventricular tissues. The upregulation of atrial and ventricular expression of PPARα, ACADM, natriuretic peptides (NPPA and NPPB), and TNF-α in SHR, was all restored by treatment of empagliflozin. CONCLUSIONS: Empagliflozin improves hemodynamics in our hypertensive heart failure rat model, associated with renal protection, attenuated cardiac fibrosis, and normalization of HF genes. Our results contribute some understanding of the pleiotropic effects of empagliflozin on improving heart function. BioMed Central 2019-04-01 /pmc/articles/PMC6444638/ /pubmed/30935417 http://dx.doi.org/10.1186/s12933-019-0849-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Lee, Hsiang-Chun
Shiou, Yi-Lin
Jhuo, Shih-Jie
Chang, Chia-Yuan
Liu, Po-Len
Jhuang, Wun-Jyun
Dai, Zen-Kong
Chen, Wei-Yu
Chen, Yun-Fang
Lee, An-Sheng
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title_full The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title_fullStr The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title_full_unstemmed The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title_short The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
title_sort sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638/
https://www.ncbi.nlm.nih.gov/pubmed/30935417
http://dx.doi.org/10.1186/s12933-019-0849-6
work_keys_str_mv AT leehsiangchun thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT shiouyilin thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT jhuoshihjie thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT changchiayuan thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT liupolen thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT jhuangwunjyun thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT daizenkong thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT chenweiyu thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT chenyunfang thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT leeansheng thesodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT leehsiangchun sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT shiouyilin sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT jhuoshihjie sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT changchiayuan sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT liupolen sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT jhuangwunjyun sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT daizenkong sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT chenweiyu sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT chenyunfang sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats
AT leeansheng sodiumglucosecotransporter2inhibitorempagliflozinattenuatescardiacfibrosisandimprovesventricularhemodynamicsinhypertensiveheartfailurerats